Amryt Pharma Share Chat (AMYT)

Find Your Broker

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Amryt Pharma	LSE:AMYT	London	Ordinary Share	GB00BDD1LS57	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-0.275p	-1.66%	16.25p	16.00p	16.50p	16.525p	16.25p	16.525p	69,744	14:00:07

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	11.4	-23.2	-10.4	-	35.24

Amryt Pharma Share Discussion Threads

Showing 4251 to 4265 of 4275 messages

Chat Pages: 171 170 169 168 167 166 165 164 163 162 161 160 Older

Date	Subject	Author	Discuss
15/1/2019 21:55	AMYT log chart. free stock charts from uk.advfn.com	papillon	Read Full Thread Reply
15/1/2019 21:22	biopharmas can damage your wealth. NSCI proves that. The NCSI share price has dropped from 72p to today's 3.35p (down 51.54% on the day) in exactly 12 months on bad newsflow. Neil Woodford's investment management has been a big loser (or rather his investors have!). NSCI's Chairman is Sir Richard Sykes a former big hitter in the pharma industry (Glaxo Wellcome & GlaxoSmithKline). Rather like AMYT's chairman, Harry Stratford, in fact. Where's the short term bottom for AMYT? Unfortunately the losses PI's have suffered at FARN, IMM, NSCI, etc hasn't helped the AMYT share price	papillon	Read Full Thread Reply
15/1/2019 11:56	Fair play to mdalos. He tipped INFA before Christmas. It's more than doubled since he mentioned it!	papillon	Read Full Thread Reply
13/1/2019 19:08	FFS. That's a pain in the hole although I was never expecting much back.	deckav	Read Full Thread Reply
13/1/2019 16:45	FASTNET HYDROCARBONS LIMITED has been dissolved (11th Dec 2018) This was the holding company for the interests of FASTNET OIL & GAS BARE TRUST. The Trsut has therefore been terminated. There will be no distribution made to the Trust beneficiaries.	mdalos1	Read Full Thread Reply
13/1/2019 12:01	I’ve just noticed that the Ph II study with diacerein in Epidermolysis Bullosa Simplex patients (study funded by Castle Creek) has been terminated, as per information on Clinicaltrials.gov website. As per information on website dated 22nd Oct 2018: ‘An Independent Data Monitoring Committee suggested that the study will not meet stated objectives’. I wonder whether the high variability in wound healing in EB Simplex patients - the reason why Amryt excluded these patients in EASE Ph III - resulted in the termination of the diacerein Ph II study? As a result, this puts a big question mark on the clinical development program for diacerein in EB, and once again highlights that Episalvan is potentially (and likely) the first drug to be approved for EB in 2020.	diamondstar1	Read Full Thread Reply
11/1/2019 13:23	You can read research articles suggesting anywhere between 60% and 90% of PIs lose money, so the best way to play the game is to do what everyone else doesn't.	the drewster	Read Full Thread Reply
11/1/2019 12:44	Well the AMYT share price may have been a very poor performer since it floated back almost 3 years ago, but I'm looking on the bright side! After all I've never bought shares in FLYB! It closed yesterday at 16.375p (not much different to that of AMYT's closing price last night). At 7am this morning FLYB issued an RNS disclosing they are recommending a takeover offer to shareholders of just ONE PENNY! Let's hope that AMYT never have to accept an offer of just ONE PENNY! :-) PS. The moral of the FLYB story? Investing in shares, especially speculative, risky, AIM listed shares, can seriously damage your wealth. It's far, far, safer to stick your money under your mattress though obviously less exciting. Gamblers invariably lose lots of money (sometimes their life savings), whether they bet on the horses, dogs, FOBT's, or AIM listed shares.	papillon	Read Full Thread Reply
11/1/2019 12:02	Good post, diamondstar. I too felt that Cathal Friel had a falling out with Joe Wiley/Rory Nealons over the future of AMYT, hence the sale of a chunk of his shareholding last May and his departure from the BoD. It looked to me that whereas Wiley/Nealons envisaged a long term future for AMYT Friel was always in it for the short term with a quick takeover his preferred outcome. Friel is a short term operator. Presumably our largest shareholder, Software AG, sided with Wiley/Nealons and not Friel. Hence Friel's decision to found Open Orphan and sell a chunk of his AMYT shares and his BoD departure.	papillon	Read Full Thread Reply
10/1/2019 23:58	Interesting point you made recently Paps that Cathal Friel was hoping for a takeover bid from the onset. I wonder whether this caused major conflict with other founding members like Joe Wiley and Rory Nealon. Has it always been Joe Wiley/Rory Nealons strategic goal to grown Amryt into the next Shire? Maybe Cathal Friel was in it for a quick sale and profit, hence why he has now sold some Amryt shares, and now invested in Open Orphan. Which has some potential conflict of interest, in terms of business model between the 2 companies. At this juncture, what implications does this have? The company has a positive interim Ph III result; the FDA priority voucher alone is worth 2-4 times is current market capitalisation. Maybe Joe Wiley does not want Amryt to be acquired by a company like Amicus, as he believes it has bigger potential. Perhaps they are more interested in a licensing deal with a Pharma partner like Allergan or even Amicus. All speculation at the moment on my behalf! But a little trivia I came across recently... Joseph Wiley’s middle name is actually Amrit. In the past, I’ve heard Joe Wiley in interviews say that the company was called Amryt because it means ‘Elixir’ in Sanskrit. But perhaps it has always his long term strategy to grow Amryt into the next Shire, as evidenced by bringing in Harry Stratford as Executive Chairman. Maybe Cathal Friel did not share Joe Wiley’s long term vision for the company? Could this have resulted in the formation of Open Orphan by Cathal Friel?	diamondstar1	Read Full Thread Reply
10/1/2019 23:50	Well the 24p warrants will expire worthless tomorrow and AMYT will lose the opportunity to gain around £5m of cash.	papillon	Read Full Thread Reply
09/1/2019 22:11	An interesting conversation is going on, on the lse bb, between Bronxville and Diamondstar as to the merits, or demerits, of AP101 as an effective treatment for EB. Of course the acid test as to whether AP101 is perceived to have value as a treatment for EB is if AMYT receives a takeover bid, by a larger biopharma, before the phase III trial is concluded, rather like the takeover of Scioderm by Amicus. Will AMYT receive a takeover bid anytime soon? No idea! Cathal Friel was hoping for one last year, two years after AMYT listed. hTTps://en.wikipedia.org/wiki/Scioderm hTTps://www.fiercebiotech.com/amicus-ditches-skin-disorder-drug-after-late-stage-failure	papillon	Read Full Thread Reply
09/1/2019 17:31	Well unless there is more good news forthcoming in the short term, via RNS, I can see the AMYT share price gradually drifting back down. That's what normally happens on AIM to an share price after the recent news has been digested and the share price has fully reacted to it. I suppose it's possible that AMYT could be the subject, in the short term, of some belated II and/or biopharma peer group (eg Amicus) buying that could lead to a rerate in the share price Of course that could be just a case of clutching at straws. At the moment the AMYT share price doesn't appear to have the "force" behind it! :-)	papillon	Read Full Thread Reply
09/1/2019 12:13	Yes, with the interim EASE results, I think we can safely say that we have moved away from generic levels of 'Probability of Technical Success' (PTS) for a Ph III trial (circa 57%), to a new level of 80%, which is based on their statistical design and actual data based on 96 patients. Gone are my previous concerns about whether Episalvan can differentiate from placebo at Day 45 (their Primary Endpoint) or whether the placebo will be acting much better than predicted (therefore reducing the treatment difference). Initially, when I read the EASE interim results and plans of increasing sample size - I must admit that I was concerned that the observed treatment difference (between Episalvan vs. placebo) will be reduced substantially, raising concerns that Drug Regulators(eg FDA) may perhaps view the results as 'Statistically Significant but not Clinically Relevant'. However, a little number crunching - and it looks to me like the treatment effect in Final EASE will still be large, circa 8-9% (assuming variability of data is as predicted). Thus, I'm hoping biotech companies like Amicus will decide to invest in Amryt at this stage or in-license the drug for the North America market. Certainly, it will be a much better investment for them compared to Zorblisa!	diamondstar1	Read Full Thread Reply
09/1/2019 11:18	As diamondstar1 states, the EASE trial interim results are incredibly encouraging. The final results are almost certainly going to be positive with a treatment effect more or less as predicted. I was so impressed with this result that I picked up a few more shares. However, it looks like the market view of this result is as mdalos1 states - keep going but not outstanding. I think this is a good example of the market getting it wrong. Time will tell.	baloo99	Read Full Thread Reply

Chat Pages: 171 170 169 168 167 166 165 164 163 162 161 160 Older

Your Recent History

LSE

AMYT

Amryt Phar..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190115 23:22:39